Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 2/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | FPR3 | P25089 | 4/20 | 0.44 |
| ▸ | FPR2 | P25090 | 4/20 | 0.44 |
| ▸ | NPC1L1 | Q9UHC9 | 3/20 | 0.42 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31206064 | 0.93 | FPR3 (0.46) | DDB1CRBNCTSKFPR3FPR2 | |
| SCHEMBL31206099 | 0.85 | CA1 (0.49) | FPR3FPR2NPC1L1EPHX1NAMPT | |
| SCHEMBL25041522 | 0.84 | CA1 (0.58) | FPR3FPR2NPC1L1NAMPTDRD2 | |
| SCHEMBL22957494 | 0.81 | DDB1 (0.43) | DDB1CRBNCTSKFPR3FPR2 | |
| SCHEMBL25042017 | 0.79 | DRD2 (0.42) | FPR3FPR2NPC1L1NAMPTDRD2 | |
| SCHEMBL22957492 | 0.77 | DDB1 (0.43) | DDB1CRBNCTSKFPR3FPR2 | |
| SCHEMBL31206120 | 0.77 | KDM1A (0.46) | NPC1L1NAMPTDRD2 | |
| SCHEMBL30817322 | 0.76 | CRBN (0.62) | DDB1CRBNFPR3FPR2MALT1 | |
| SCHEMBL22644748 | 0.76 | MALT1 (0.51) | DDB1CRBNCTSKFPR3FPR2 | |
| SCHEMBL21659730 | 0.75 | POLB (0.56) | DDB1CRBNMALT1BCHECA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360114-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360114-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | AIFM2, GPX1, GPX4 | DDB1 1180/4885CRBN 2564/4885CTSK 1490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.